KZIA

Kazia Therapeutics Limited - ADR

7.19

USD

KZIA Earnings Reports

Positive Surprise Ratio

KZIA beat 2 of 6 last estimates.

33%

Next Report

Date of Next Report

Estimate for Q-- -- (Revenue/ EPS)

Implied change from Q2 26 (Revenue/ EPS)

Implied change from Q-- -- (Revenue/ EPS)

Kazia Therapeutics Limited - ADR earnings per share and revenue

On Mar 19, 2026, KZIA reported earnings of -0.80 USD per share (EPS) for Q2 26, missing the estimate of -0.33 USD, resulting in a -142.84% surprise. Revenue reached 253.00 thousand, compared to an expected 51.00 thousand, with a 396.08% difference. The market reacted with a -5.44% price change (close before vs. close after earnings).

Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Precigen, Inc. Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.08

Actual

-$0.01

Surprise

+88.24%

Absci Corporation Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.19

Actual

-$0.23

Surprise

-16.04%

Candel Therapeutics, Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.25

Actual

-$0.54

Surprise

-115.31%

LENZ Therapeutics, Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.99

Actual

-$1.15

Surprise

-17.10%

Fennec Pharmaceuticals Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

$0.03

Actual

-$0.11

Surprise

-408.12%

Equillium, Inc. Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.06

Actual

-$0.04

Surprise

+35.28%

MaxCyte, Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.08

Actual

-$0.06

Surprise

+26.47%

Celcuity Inc. Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$1.06

Actual

-$0.97

Surprise

+8.72%

TELA Bio, Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.18

Actual

-$0.16

Surprise

+14.12%

Dyadic International, Inc.

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.04

Actual

-$0.06

Surprise

-30.72%

FAQ

What were Kazia Therapeutics Limited - ADR's earnings and revenue for the latest quarter Q2 2026?

For Q2 2026, Kazia Therapeutics Limited - ADR reported EPS of -$0.80, missing estimates by -142.84%, and revenue of $253.00K, 396.08% above expectations.

How did the market react to Kazia Therapeutics Limited - ADR's Q2 2026 earnings?

The stock price moved down -5.44%, changed from $7.91 before the earnings release to $7.48 the day after.

When is Kazia Therapeutics Limited - ADR expected to report next?

The next earning report is scheduled for --.

What are the forecasts for Kazia Therapeutics Limited - ADR's next earnings report?

Based on -- analysts, Kazia Therapeutics Limited - ADR is expected to report EPS of -- and revenue of -- for Q-- --.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.